Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 4
2010 3
2011 6
2012 8
2013 3
2014 7
2015 18
2016 19
2017 21
2018 15
2019 16
2020 16
2021 14
2022 10
2023 12
2024 16
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

181 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group. Muppidi S, et al. Muscle Nerve. 2019 Jul;60(1):14-24. doi: 10.1002/mus.26447. Epub 2019 Mar 8. Muscle Nerve. 2019. PMID: 30767274 Free PMC article.
Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, Pittock SJ; PREVENT Study Group. Wingerchuk DM, et al. Ann Neurol. 2021 Jun;89(6):1088-1098. doi: 10.1002/ana.26049. Epub 2021 Feb 27. Ann Neurol. 2021. PMID: 33586143 Free PMC article. Clinical Trial.
Suzetrigine for moderate to severe acute pain.
Cho EB, Jiang C, Wang Z, Yu Y, Jiang J. Cho EB, et al. Trends Pharmacol Sci. 2025 May;46(5):480-481. doi: 10.1016/j.tips.2025.02.008. Epub 2025 Mar 24. Trends Pharmacol Sci. 2025. PMID: 40133193
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Adams D, et al. Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16. Lancet Neurol. 2021. PMID: 33212063 Free article. Clinical Trial.
Hydroxychloroquine-induced hyperpigmentation.
Cho EB, Kim BC, Park EJ, Kwon IH, Cho HJ, Kim KH, Kim KJ. Cho EB, et al. J Dermatol. 2012 Oct;39(10):859-60. doi: 10.1111/j.1346-8138.2012.01591.x. Epub 2012 Jun 1. J Dermatol. 2012. PMID: 22671572 No abstract available.
Potential prognostic value of rheumatoid factor in anti-aquaporin 4-immunoglobin G-positive neuromyelitis optica spectrum disorders.
Lee HL, Seok JM, Hwang SY, Cho EB, Kim H, Shin HY, Kim BJ, Baek SH, Seok HY, Kang SY, Kwon O, Lim YM, Lee SS, Oh J, Huh SY, Kim JK, Yoon BA, Sohn EH, Kim S, Cho JY, Min JH, Kim BJ. Lee HL, et al. Among authors: cho eb. J Neurol Sci. 2024 Nov 15;466:123215. doi: 10.1016/j.jns.2024.123215. Epub 2024 Sep 4. J Neurol Sci. 2024. PMID: 39243603
Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea.
Kim SH, Min JH, Kim SM, Lee EJ, Lim YM, Shin HY, Kwon YN, Sohn E, Kim S, Park MS, Nam TS, Yoon BA, Kim JK, Shin KJ, Kim YH, Seok JM, Bong JB, Kim S, Seok HY, Oh SY, Kwon O, Kim S, Lee S, Kim NH, Cho EB, Kang SY, Oh SI, Bae JS, Ahn SW, Kim KH, Kang YR, Ju W, Choo SH, Chung YH, Hyun JW, Kim HJ. Kim SH, et al. Among authors: cho eb. J Clin Neurol. 2025 Mar;21(2):131-136. doi: 10.3988/jcn.2024.0485. J Clin Neurol. 2025. PMID: 40065454 Free PMC article.
181 results